Return to the catalog
Retatrutide
NewIn Stock30mg vial

Retatrutide

Triple-receptor compound studied for appetite, blood-sugar, and body-weight regulation.

For Research Use Only

Sold strictly for laboratory research. Not for human or veterinary use, ingestion, or clinical/diagnostic application.

1–4 vialsR 1650.00
5+ vials — save 18%R 1350.00 each

The lower price is applied automatically once your cart holds 5 or more of this vial.

Bacteriostatic water included

99%+ Purity
Extensively Researched
1

About this peptide

Retatrutide is an investigational triple-receptor agonist peptide. It acts on GLP-1, GIP, and glucagon receptors, three signalling systems involved in appetite, blood-sugar control, and how the body uses stored energy. Researchers study this combined action in metabolic and body-weight regulation models.

Why researchers reach for Retatrutide

Triple-receptor pharmacology

Simultaneously engages GLP-1, GIP and glucagon receptors.

Adiposity models

Referenced across rodent DIO and NHP obesity studies.

Glucose regulation

Preclinical data on insulin secretion and hepatic glucose output.

Key features

  • ≥99% HPLC purity
  • Fatty-acid conjugated backbone
  • Mass-spec verified
  • Cold-chain dispatch

How it works

Incretin signaling

Amplifies glucose-dependent insulin release via GLP-1 and GIP receptors.

Glucagon-mediated energy expenditure

Adds glucagon receptor engagement for thermogenic tone in animal models.

Extended half-life

Albumin-binding fatty acid moiety supports weekly dosing paradigms in research.

Research dosage guidelines

Reference ranges only — reproduced from published preclinical literature. Not a recommendation for human use.

RangeReported doseNote
Typical reconstitution2 mL bacteriostatic waterYields 15 mg/mL (15 000 mcg/mL)
Reported research range2–12 mg/week (titrated)Reference only

Tracking this compound? Registered researchers can log active Retatrutide protocols in their private Research Log.

Timing in research protocols

Once weekly on a consistent day; time of day is pharmacologically immaterial.

  • The phase 2 randomised trial (Jastreboff et al., NEJM 2023) used once-weekly subcutaneous dosing for 48 weeks, with dose escalation and a 24-week primary endpoint.
  • The half-life for this receptor-agonist class is roughly 6 days, so plasma levels do not track the clock.
  • The protocol did not specify or test time of day or fasting state; consistency of the weekly dosing day is the operative variable.
  • Published study duration: up to 48 weeks with stepwise escalation.

Drawn from published research protocols and pharmacology literature. Reference information for laboratory research only — not an instruction or guidance for use.

Technical specifications

Class
GLP-1 / GIP / glucagon triple receptor agonist
Peptide structure
39-residue Aib-substituted peptide, C20 fatty-acid conjugated
Molecular weight
~4731 g/mol
Purity
≥99% (HPLC)
Form
Lyophilized powder
Vial size
30 mg
Storage (lyophilised vial)
Cool, dry and protected from light
Storage (after reconstitution)
2–8°C

Published research

Peer-reviewed literature on Retatrutide. Links open in a new tab.

Research use notice

Sold for in vitro laboratory research only. Not for human or veterinary use, diagnosis, or therapy.

#incretin#triple-agonist#metabolic#weight-research

Cart (0)

Your cart is empty